← board
CNTB
Connect Biopharm LLCdistress 6/10 · elevated risk$2.190%today-41% from 52w high
Respiratory 2
Lead: moderate-to-severe asthma · est. market ~$22B (approx, global)
Revenue
pre-revenue
Liquidity
$46M
Runway
0.8 yrs
Shares 1y
+13%
Price & events
-17.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-6.2%
1W
+4.8%
1M
-13.1%
3M
-13.8%
6M
-3.5%
1Y
+65.9%
2Y
-91.6%
5Y
-88.2%
All
Overview
- Market Cap
- $137.89M
- Volume
- 28.99K
- 52 Week Range
- $1.32 – $3.69
- Total Shares
- 62.96M
- Float Shares
- 18.85M
- Short %
- 2.99%
- % Held by Insiders
- 31.82%
- % Held by Institutions
- 55.58%
- RVOL
- 0.05x
Pipeline stages · 1 programs
Matching placebo in prefilled syringe
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-13 Estimated 50% readout ~2026-08-27 final ~2027-01-13 | Phase 2 | — | Asthma Acute | 160 | active not recruiting |
| 2026-06 | Phase 2 | Matching placebo in prefilled syringe | COPD Acute Exacerbation | 160 | recruiting |
Catalyst news & presentations · 5
- first half of 2026readoutPhase 2rademikibart · Topline data from Phase 2 Seabreeze STAT COPD studySEC 8-K
- first half of 2026readoutPhase 2rademikibart · Topline data expected from Phase 2 Seabreeze STAT Asthma study.SEC 8-K
- submittedregulatory submissionFiled (NDA/BLA)rademikibart · NDA submitted to NMPA for treatment of atopic dermatitis in adults and adolescentsSEC 8-K
- second quarter of 2025trial initiationsecondaryPhase 2rademikibart · Enrolling patients in parallel Phase 2 trials for asthma and COPD with acute exacerbation.SEC 8-K
- 2025-05-14fda agreementrademikibart · FDA provided written agreement on final study protocol for Phase 2 COPD studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+225% upside) · 8 analysts
- 2026-07-09OppenheimerOutperform
- 2026-06-26Piper SandlerNeutral → Overweight
- 2026-06-25HC Wainwright & Co.Buy
- 2026-05-26Canaccord GenuityBuy
- 2026-05-21Cantor FitzgeraldOverweight
- 2026-04-01BTIGBuy
Competitors — moderate-to-severe asthma
- APGEApogee Therapeutics, Inc.— · D2
Recent news
- 2026-07-16BIO 2026: Catching Up With Vaxart, Aphaia, Connect Biopharma, Kyverna And Chugai - insights.citeline.com
- 2026-07-09CNTB Initiates Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
- 2026-07-09Oppenheimer initiates Connect Biopharma stock with outperform rating - Investing.com
- 2026-07-01Connect Biopharma (NASDAQ: CNTB) director receives 6,718-share award as 2026 board compensation - Stock Titan
- 2026-06-26Piper Sandler initiates Connect Biopharma stock with overweight rating - Investing.com
- 2026-06-25H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 By Investing.com - Investing.com Canada
- 2026-06-25H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 - Investing.com
- 2026-06-18Connect Biopharma Holdings Ltd (CNTB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.